Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 U.S. States for Climbing - 2Best bar-b-que Style: Which One Is Your Number one?
- 3Tickets for 'Stranger Things' Season 5 finale, to be shown in movie theaters on New Year's Eve, go on sale today. Here's how you can save your seat.
- 4Kelsey Grammer on having a new baby at 70: 'You're just more available now'
- 5Stop the ‘good’ vs ‘bad’ snap judgments and watch your world become more interesting
- 'The Golden Bachelor' Season 2 finale: How to watch tonight, start time, where to stream and more
- The Best Web-based Courses for Ability Advancement
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- 6 US States for Fly Fishing
- FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- New funding transforms lives by expanding electricity access across Africa
- Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- Famous Versatile Brands: Your Decision
- 'Stranger Things' series finale trailer shows Hawkins gang gearing up for last battle with Vecna
